Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS

Vascular endothelial dysfunction has been demonstrated in metabolic syndrome (MS). Chronic administration of rosiglitazone ameliorates endothelial dysfunction through PPARγ-mediated metabolic improvements. Recently, studies suggested that single dose of rosiglitazone also has direct vascular effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhigang, Luo, Zhidan, Wang, Peijian, Sun, Jing, Yu, Hao, Cao, Tingbing, Ni, Yinxing, Chen, Jing, Yan, Zhencheng, Liu, Daoyan, Zhu, Zhiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236323/
https://www.ncbi.nlm.nih.gov/pubmed/22190906
http://dx.doi.org/10.1155/2011/291656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236323/
https://www.ncbi.nlm.nih.gov/pubmed/22190906
http://dx.doi.org/10.1155/2011/291656

Ejemplares similares